Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Our purpose is to progress iconic medicines for the benefit of patient health globally. We aspire to be an agile and imaginative specialty pharma business and a preferred partner for innovator pharma companies.
More about us10+
Offices
20+
Brands
140+
Markets
200+
Employees
Our key products include Inderal®, Tenormin®, Tenoretic®, Zestril®and Zestoretic®
Our key products include Bonviva®, Rocaltrol® and Synacthen®
Our key products include Anaprox®, Naprosyn®, Toradol® and Valium®
Our key products include Bondronat®, Dipentum® and Kytril®
We work with innovator pharma companies on the late stage activities of development, co-development, licensing and established brand acquisition. We aim to be open, approachable and collaborative. We pride ourselves on our entrepreneurial heritage and we retain a dynamic, motivated and “can do” attitude. We have an enviable track record and repeat transactions bear testament to our status as a preferred partner.
Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,...
More informationBasildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial...
More informationBasildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in...
More informationWe are an experienced group of people with a can-do attitude. We believe in openness, honesty and courtesy, and value collaboration above all else. If you are a motivated and dynamic individual, we can empower you and you will thrive with us.
We are proud to be a member of EMIG, the Ethical Medicines Industry Group.
Learn more at emig.org.uk
